Alexza Pharma (ALXA) Reports Q4 Loss of $0.15/Share; Warns it May Shut Down

Alexza Pharma (NASDAQ: ALXA) reported Q4 EPS of ($0.15), versus ($0.35) reported last year. Revenue for the quarter came in at $673 thousand, versus $1.45 million reported last year.

Alexza believes that, based on its cash and cash equivalent balances at December 31, 2015, the additional $1.0 million drawn in March 2016 under the promissory note issued to Ferrer in September 2015, and it's expected cash usage, it has sufficient capital resources to meet its anticipated cash needs until the end of April 2016. Changing circumstances may cause the Company to consume capital significantly faster or slower than currently anticipated, or to alter the Company's operations. Even if circumstances do not cause Alexza to consume capital significantly faster or slower than currently anticipated, Alexza may be forced to significantly reduce operations if its business prospects do not improve. If Alexza is unable to source additional capital, it may be forced to shut down operations altogether.

For earnings history and earnings-related data on Alexza Pharma (ALXA) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Deere (DE) PT Lowered to $570 at JPMorgan Ahead of Earnings
• Bernstein SocGen Group Reiterates Outperform Rating on JD.com, Inc (JD), 'very cheaply valued'